Introduction
Prostate cancer is the second leading cause of cancerrelated mortality for men in the United States (Greenlee et al., 2000) . The established protocol for treating the advanced stage of this disease is surgical castration and/ or chemotherapy to eliminate circulating androgens (Epstein et al., 1996) . Activation of the androgen receptor by androgens is required for cell proliferation in the prostate. Therefore, androgen ablation therapy is initially effective in inhibiting cancer cell growth in most patients. However after a period of time, the tumor recurs in an androgen-refractory manner with a more aggressive and metastatic phenotype, ultimately leading to patient death (Kyprianou et al., 1990; Denis and Murphy, 1993; Oh and Kantoff, 1998; Isaacs, 1999) . As the detailed molecular mechanism underlying the metastatic spread of prostate cancer is poorly understood, it has therefore been difficult to develop effective treatments at this stage of the disease. Initially, the concept of clonal selection was thought to explain the progression of the disease but subsequent molecular investigations of the androgen receptor (AR) provided a more mechanistic approach to understanding the metastatic progression of prostate cancer during androgen deprivation. Possible mechanisms for AR re-activation include AR gene mutation, gene amplification, the involvement of coregulators, and crosstalk between different signal transduction pathways (Sadar et al., 1999) .
Apart from the possibilities discussed above, the involvement of other pathological mechanisms cannot be dismissed. In this regard, angiogenesis represents an effective target mechanism (Stewart et al., 2001; Nicholson and Theodorescu, 2004; Gustavsson et al., 2005) . Angiogenesis is a process by which new vasculature is developed from pre-existing vessels and it is particularly important for the growth and metastasis of most human tumors (Folkman, 1971; Holash et al., 1999; Carmeliet, 2000) . There have been previous reports that androgens may potentially modulate angiogenesis in animal and human prostate tumors by increasing vascular endothelial growth factor (VEGF) gene transcription (Stewart et al., 2001) . As a result, an initial and rapid vascular regression in the tumor occurs after hormone withdrawal. Interestingly, progression of prostate cancer to an androgen-independent stage is also associated with increased angiogenesis. The lack of angiogenic regulation by androgens may be an additional factor accompanying the transition to this stage of androgen resistance (Jain et al., 1998) . Therefore, it is important to identify any regulatory dysfunction of angiogenic growth factors during androgen-refractory stage of prostate cancer.
VEGF-A is the founding member of closely related cytokines that exert critical functions in vasculogenesis, pathologic and physiologic angiogenesis and lymphangiogenesis (Dvorak et al., 1995; Dvorak, 2000; Ferrara, 2001) . Other members of the VEGF family include VEGF-B, VEGF-C, VEGF-D, VEGF-E (orf virus VEGF) and placental growth factor (P1GF) (Chilov et al., 1997; Enholm et al., 1997; Achen et al., 1998 Achen et al., , 2002 Olofsson et al., 1999; Dvorak, 2000; Carmeliet et al., 2001) . All of these ligands mainly bind to and activate three receptor tyrosine kinases (TRK) to initiate their downstream signaling. These TRKs include: VEGFR-l/Flt-1, VEGFR-2/Flk-l/KDR and VEGFR-3/Flt4. VEGF-A binds to VEGFR-1 and VEGFR-2 whereas VEGF-C and -D bind to VEGFR-2 and VEGFR-3. VEGF-B binds only VEGFR-1 and VEGF-E binds only VEGFR-2 (de Vries et al., 1992; Dvorak et al., 1995; Hatva et al., 1995; Kaipainen et al., 1995; Joukov et al., 1996; Dvorak, 2000; Kubo et al., 2000; Veikkola et al., 2000) . There is also a fourth nontyrosine kinase receptor called neuropilin-1 that mainly binds VEGF-A (Soker et al, 1998) .
Among the angiogenic cytokines, VEGF-C draws special attention because of its potential involvement in the lymph node metastasis of several cancers includingcolorectal cancer, human pancreatic endocrine tumors, esophageal carcinomas, head and neck squamous cell carcinoma, uterine cervical cancer, primary non-smallcell lung cancer, gastric carcinoma, and laryngeal squamous carcinoma (Yonemura et al., 1999; Hashimoto et al., 2001; Kimura et al., 2003; Neuchrist et al., 2003; Jia et al., 2004; Sipos et al., 2004; Wang et al., 2004) . Recently, Tsurusaki et al. reported a significant correlation between the expression of VEGF-C and lymph node dissemination in human prostate carcinoma (Tsurusaki et al., 1999) . They found an increased number of vessels positive for VEGFR-3, the VEGF-C receptor, in surrounding stromal tissue of VEGF-C positive prostatic carcinoma cells (Tsurusaki et al., 1999; Zeng et al., 2004) . VEGF-C has a high degree of sequence homology with VEGF-A. It also has eight-conserved cysteine residues involved in intraand intermolecular disulfide bonding. The cysteine-rich COOH-terminal increases the length of VEGF-C by half as compared to other VEGF family members. VEGF-C, like VEGF-A, has alternative spliced forms. VEGF-C mRNA is first translated into a precursor that, after secretion, undergoes cell associated proteolytic processing. The mature form of VEGF-C is attained after the proteolytic removal of its NH 2 -and COOHterminal extensions. Mature form has increased binding affinity towards VEGFR-3 by approximately 400-fold. It can also bind to VEGFR-2 while the unprocessed form of VEGF-C can bind only VEGFR-3 (Lee et al., 1996; Pepper, 2001) . The mature form can induce endothelial cell proliferation and migration as well as vascular permeability . Despite these reports, the individual role of each receptor on VEGF-C stimulation is not yet clear. In contrast to VEGF-A, VEGF-C is not regulated by hypoxia (Enholm et al., 1997) . The expression profile of VEGF-C and its binding to VEGFR-3 suggests its involvement in the development of the lymphatic system or lymphangiogenesis in the tumor microenvironment.
Cytokines such as VEGF-C are multifunctional in nature. Therefore, increased expression of VEGF-C in the tumor microenvironment will trigger an enhancement of many cellular functions and deregulate the balance between different physiological processes. One possible function of VEGF-C in the tumor microenvironment mentioned before is that of lymphangiogenesis, providing a potential route for tumor cell dissemination to the lymph node. Because, this may not be the only function of VEGF-C-promoting metastasis, it will be interesting to study the potential functions of VEGF-C, apart from lymphangiogenesis, that may be responsible for the progression of prostate cancer to the androgen-refractory condition. It has been reported that VEGF-C can stimulate proliferation and migration of Kaposi's sarcoma cells (Marchio et al., 1999) and also proliferation and survival for leukemia (Dias et al., 2002) . Again, lack of lymphangiogenesis observed in uveal melanoma despite its high expression of VEGF-C, suggests a different function in cancer progression (Clarijs et al., 2001) .
In the androgen-dependent prostate cancer cell line LNCaP, we have observed VEGF-C expression. Furthermore, androgen withdrawal upregulates VEGF-C expression in LNCaP cells. Our data suggest that the androgen receptor (AR)-IGF-IR axis is important for the observed VEGF-C transcriptional upregulation in LNCaP. Again, an increase in Bag-1L protein level by VEGF-C was observed in LNCaP cells that may provide an explanation for activation of androgen receptor by VEGF-C in low androgen concentration.
Results

VEGF-C is highly expressed in metastatic prostate cancer cell line
Previous reports suggest a positive correlation between VEGF-C expression and the metastatic potential of human prostate cancer cells. In order to test whether a greater metastatic potential correlates with higher expression levels of VEGF-C, we used real-time PCR to quantify VEGF-C mRNA levels in three prostate cancer cell lines: PC-3, DU145, and LNCaP ( Figure 1a) . The VEGF-C mRNA level in each cell line was normalized to the housekeeping gene 36B4. Interestingly, the VEGF-C mRNA level in PC-3, the cell line with the highest metastatic potential, was 250-fold higher than that of LNCaP, the cell line with the lowest metastatic potential. DU145, intermediate in terms of metastatic potential, expressed VEGF-C mRNA at levels 150-fold greater than that of LNCaP but lower when compared to that of PC-3. Although VEGF-A mRNA levels were only two fold higher in the PC-3 cell line and four fold higher in the DU145 with respect to LNCaP, the levels were clearly not as high as VEGF-C (Figure 1b) . Protein levels of VEGF-C in PC-3 and LNCaP cell lines were also in line with the real-time PCR data when tested by ELISA (Figure 1c ). Taken together, these results pointed to the potential importance of VEGF-C in prostate cancer metastasis.
The more metastatic subline LNCaP expresses higher levels of VEGF-C VEGF-C protein levels were also tested in LNCaP-Pro5 and LNCaP-LN3, two different sublines of LNCaP with a greater metastatic potential than the parental cell line (Pettaway et al., 1996) . We performed ELISA to quantitate the VEGF-C protein amount in the conditioned media of different LNCaP sublines (Figure 1d ). The most metastatic subline LNCaP-LN3 expressed highest amount of VEGF-C. LNCaP-pro5 was intermediate in terms of metastatic potential among the sublines and expressed more VEGF-C protein than the parental cell line but less compared to LNCaP-LN3.
Western blot results (Figure 1e ) also show higher VEGF-C protein levels in both LNCaP-Pro5 and LNCaP-LN3 compared to the parental LNCaP line. These results again suggested the potential involvement of VEGF-C in metastasis.
Androgen negatively regulates VEGF-C levels in LNCaP cells
It is known that androgen deprivation is associated with the gradual transition of prostate cancer from the androgen-dependent stage to the androgen-refractory stage. Furthermore, the tumor recurs with a more metastatic phenotype. This prompted us to investigate whether androgen can regulate VEGF-C expression in LNCaP cells. LNCaP cells were grown in media with charcoal-dextran-treated serum (reduced androgen-containing serum) for 48, 72, 96, and 120 h. Using real-time PCR, we observed a time-dependent upregulation of VEGF-C mRNA across the time points tested (Figure 2a ), suggesting a negative regulation of VEGF-C expression by androgen. The value of VEGF-C mRNA level at each time point was normalized with the value of the house keeping gene 36B4. This result was confirmed when the upregulation of VEGF-C mRNA level was significantly inhibited after the addition of synthetic androgen (R1881) to the charcoal-treated media at the 48-h time point (Figure 2b) . Additionally, the negative regulation of VEGF-C by androgen appears specific because a different profile was observed for VEGF-A mRNA. VEGF-A mRNA levels decreased in the absence of androgen but increased significantly when R1881 was added to the media (Figure 2c ).
Functional inhibition of insulin-like growth factor-I (IGF-IR) signaling upregulates VEGF-C mRNA level
Recently, Arnold et al. (2005) described a functional correlation between androgen and IGF-IR expression in prostate cancer cells. They showed that androgen stimulation of LNCaP cells cultured in media containing charcoal-dextran-treated serum led to an increase in IGF-IR protein expression. We also observed the similar regulation of androgen for IGF-IR expression in LNCaP as shown in (Figure 3a ). This result suggests the possible regulation of IGF-IR synthesis by androgens. In another report, Plymate et al. (2004) described that the progression from an organ-confined tumor to metastatic prostate cancer was characterized by a deregulation of the androgen receptor and a decrease in IGF-IR protein expression. These two findings suggest that decreasing IGF-IR levels plays a role on the progression of prostate cancer to its androgenrefractory, metastatic stage. Since androgen withdrawal also increases VEGF-C mRNA levels, we investigated whether IGF-IR also influenced regulation of VEGF-C transcription. Our real-time PCR data ( Figure 3b ) suggest a 8-10-fold increase in VEGF-C mRNA when blocking antibody specific for the IGF-IR receptor (Keller et al., 1993; De Meyts et al., 1995; Datta et al., 2000; Schlessinger, 2000) inhibited IGF-IR signaling. We also observed the increase in VEGF-C mRNA level in both the LNCaP-Pro5 and LNCaP-LN3 cells by inhibiting IGF-IR signaling (Figure 3c and d). The reason for not detecting the 8-10-fold increase in VEGF-C mRNA like parental LNCaP cell line was probably due to the fact that these two cell lines are more metastatic than LNCaP cells and already express higher level of VEGF-C (Figure 1d ). Again, we did not observe any significant increase in VEGF-A mRNA in LNCaP cells when we inhibited the IGF-IR pathway suggesting a VEGF-C-specific phenomenon ( Figure 3e ). These results, therefore, correlate a possible link between androgen withdrawals, a decrease in IGF-IR protein expression, and VEGF-C upregulation in prostate cancer cells.
FOXO-1 is the potential transcription factor for VEGF-C and is activated by SIRT-1
Forkhead transcription factors become functionally active due to the downregulation of IGF-IR signaling. PKB or AKT activation by the IGF-IR-phosphoinositide-3 kinase (PI3K) pathway leads to the phosphorylation of forkhead transcription factors, which retains them in the cytoplasm (Borkhardt et al., 1997; Kops and figure) for 48, 72, 96 and 120 h. Total RNAs were obtained in each time point followed by RT-PCR using primers specific for VEGF-C and 36B4 (internal control). For the control experiment, LNCaP cells were cultured in the normal serum-containing media for the same time points described above and VEGF-C mRNA level was determined by RT-PCR. The data showed here are the average of three independent results. (b and c) LNCaP cells were first cultured in charcoal-dextran-treated serumcontaining media (designated as CS in the figure) for 48 h. R1881 (1 mM) was then added to the media and the total RNA was isolated at the different time points with respect to the cells cultured in charcoal-stripped media. RT-PCR was performed with the total mRNA by using primers specific for VEGF-C (b) and specific for VEGF-A (c). 36B4 mRNA levels were monitored in every experiment for internal control. The data showed here are the average of three independent results Androgen depletion upregulates VEGF-C J Li et al Burgering, 1999; Lin et al., 1997; Morris et al., 1996; Ogg et al., 1997) . Therefore, inhibition of the IGF-IR signaling pathway should lead to the less phosphorylation of forkhead transcription factors, allowing them to enter the nucleus and promote the transcription of their target gene. Using the Genomatix software available on the internet (http://www.genomatix.de), we searched the known promoter region of VEGF-C for potential binding sites of transcriptional regulators and found several for the forkhead transcription factor, FOXO-1. To study whether FOXO-1 could indeed upregulate VEGF-C transcription, we transiently overexpressed FOXO-1 in LNCaP cells and used real-time PCR to monitor VEGF-C mRNA levels (Figure 4a ). With the transient overexpression FOXO-1, we found a significant increase in VEGF-C mRNA levels. FOXO-1 protein overexpression was detected by Western blot with the anti-FLAG antibody (Figure 4b ).
Various biological functions controlled by FOXO-1 include cell cycle arrest, detoxification of reactive oxygen species, repair of damaged DNA, and apoptosis (Kops and Burgering, 1999) . Recent reports suggest that the presence of SIRT1 (mammalian homolog of yeast silencing information regulator 2 (Sir2) gene) enhances the expression of the FOXO target genes involved in stress resistance but diminishes the expression of proapoptotic genes like Fas ligand and BIM. Sir2 has been shown to play a role in increasing the lifespan of yeast and Caenorhabditis elegans and is conserved throughout evolution. It is a nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylase. Forkhead transcription factors have been shown to be a target of SIRT1. Deacetylation of FOXO transcription factors by SIRT1 is specifically required for the transcription of stress resistance genes, such as genes that control the repair of damaged DNA (GADD45) (Araki et al., 2004; Brunet et al., 2004; Cohen et al., 2004; Daitoku et al., 2004) . Because the VEGF family is known to be involved in lymphangiogenesis, angiogenesis, and survival, we studied the involvement of SIRT1 in the FOXO-1-dependent transcription of VEGF-C. We found that BML-210, a specific SIRT1 inhibitor, abrogated FOXO-1 dependent VEGF-C transcription (Figure 4c ). This result was confirmed when we used the dominant-negative form of SIRT1 to inhibit its activity (Figure 4d ). SIRT-1DN protein overexpression was detected by Western blot with the anti-FLAG antibody (Figure 4e ). Since androgen withdrawal leads to inhibition of PI3K-AKT pathway (Baron et al., 2004; Castoria et al., 2004; Kang et al., 2004) and therefore potentially activates FOXO-1, we tested whether dominant-negative form of SIRT-1 could abrogate the increase in VEGF-C expression in LNCaP due to androgen withdrawal. Our result (Figure 4f ) clearly indicated the involvement of SIRT-1 in androgenregulated VEGF-C transcription. These results are significant as they provide a mechanistic explanation for how FOXO-1, activated by SIRT1, can act to . LNCaP cells were grown in 0.1% FBS for overnight. Anti-IGF-IR blocking antibody (5 mg/ml) either alone or along with BML-210 (10 mM) was then added for 8 h. Normal mouse IgG (5 mg/ml) was also used separately either alone or along with BML-210 (10 mM) for control experiment. Total RNA was isolated for each set and real time PCR was performed for VEGF-C and 36B4 (internal control). In the figure, IgG stands for normal mouse IgG antibody and IGF-IR stands for anti-IGF-IR blocking antibody. The data here represent mean of three separate assays. (d) Overexpression of dominant-negative form of SIRTl decrease the VEGF-C mRNA level. LNCaP cells transiently transfected with plasmid expressing dominant-negative form of SIRT1 (1.5 mg, pECE-SIRT-lDN)) in the presence or absence of anti-IGF-IR antibody (5 mg/ml). Total RNA was extracted from LNCaP cells and mRNA level of VEGF-C was determined by RT-PCR using primers specific for VEGF-C and 36B4 (internal control). In the figure, EV represents empty vector, pECE. IgG stands for normal mouse IgG antibody and IGF-IR stands for anti-IGF-IR blocking antibody. The data here represent mean of three separate assays. (e) Western blot was performed using anti-flag antibody with the whole cell lysate extracted from the LNCaP cells transiently transfected with 1.5 mg of Flag-SIRT-IDN plasmid.
(f) Overexpression of dominant-negative form of SIRT1 decrease the VEGF-C mRNA level induced by androgen depletion. LNCaP cells transiently transfected with either plasmid expressing dominant-negative form of SIRT1 (1.5 mg) or empty vector (EV) and cultured in the presence of charcoal-dextran-treated serum-containing media for 72 h. For control experiment, LNCaP cells were cultured in the normal serum-containing media. Total RNA was extracted from LNCaP cells and mRNA level of VEGF-C was determined by RT-PCR using primers specific for VEGF-C and 36B4 (internal control). The data here represent mean of three separate assays
Androgen depletion upregulates VEGF-C J Li et al transcribe VEGF-C under androgen withdrawal condition and it also indicates that VEGF-C is another target gene for SIRT1.
VEGF-C can increase the expression of the transcription coactivator BAG-IL in LNCaP
VEGF family members are multifunctional growth factor proteins. The established function of VEGF-C is to potentiate the growth and sprouting of lymphatic endothelial cells or lymphangiogenesis by binding its receptor VEGFR-3. It is therefore important to determine the contribution of lymphangiogenesis to the survival and metastasis of prostate cancer cells during their transition to the androgen-refractory stage. In a recent report, Rafi et al. showed that expression of the antiapoptotic protein Bcl-2 was increased in the leukemia cells after treatment with VEGF-C (Dias et al., 2002) suggesting a function distinct from lymphangiogenesis. In the prostate cancer cell line LNCaP, the mRNA level of VEGFR3 was low and at least 10-fold lower than VEGFR2 as detected by real-time PCR (Figure 5a ). The relative expression levels of these two receptors in the lymphatic endothelial cells (kind gift from Dr Mihaela Skobe) were also tested as a control experiment (Figure 5b ). Figure 5a therefore indicated a potential VEGF-C-VEGFR-2-mediated autocrine pathways in LNCaP. A similar autocrine loop for VEGF-A-VEGFR2 in LNCaP cells were also reported by Steiner et al. (2004) . Although VEGF-C is known to bind VEGFR-2, the significance of this binding is not known. Interestingly, we observed an increase in the expression of Bag-1 long isoform (Bag-IL) after treating serumstarved LNCaP cells with recombinant VEGF-C protein for 24 h (Figure 5c ). Several reports suggested that the transcriptional coactivator, Bag-IL enhances the transactivation function of androgen receptor (Froesch et al., 1998; Shatkina et al., 2003) . Therefore, an increase in Bag-IL protein level by VEGF-C may therefore provide an explanation of VEGF-C-mediated androgen receptor activation in the low concentration of androgen.
Discussion
A detail molecular understanding of the gradual transition of prostate tumors from androgen dependence to androgen independence during androgen ablation therapy is necessary to design an effective therapy against this stage of the disease. Although some mechanisms have been postulated for androgen receptor activation, the involvement of angiogenic growth factors provides an alternative avenue of study. It is possible that angiogenic growth factors may act independently or in conjugation with the androgen receptor, to regulate the survival and metastasis of the androgen-refractory stage of prostate cancer. The possible crosstalk between the androgen receptor and angiogenic growth factors was first established by observing that androgens may modulate angiogenesis in animal and human prostate tumors, potentially by increasing vascular endothelial Serum-starved LNCaP cells were incubated with recombinant VEGF-C protein (100 ng/ml) for 24 h. The proteins of the whole cell lysates were resolved by SDS-PAGE followed by Western blot using antibody specific for Bag-1. This antibody also recognizes Bag-IL (the long isoform) at 58 kDa. Membrane was then stripped for Western blot against b-actin (lower panel). The Western blot was repeated more than three times
Androgen depletion upregulates VEGF-C J Li et al growth factor-A (VEGF-A) gene transcription (Jain et al., 1998; Stewart et al., 2001) . As a result, an initial and rapid vascular regression occurs after hormone withdrawal in prostate cancer. Surprisingly, however, progression of prostate cancer into an androgenindependent stage is also associated with increased angiogenesis. Thus far, the mechanism of this second wave of angiogenesis is unknown. Interestingly, VEGF-C, another VEGF family member, is also expressed in human metastatic prostate cancer specimens. An increased number of vessels positive for VEGFR-3, the VEGF-C receptor, has been reported in the surrounding stromal tissue of VEGF-C positive prostatic carcinoma cells (Skobe et al., 2001; Zeng et al., 2004) . Taken together, these reports suggest the importance of VEGF-C in prostate cancer metastasis. We have observed an increase in VEGF-C mRNA and protein in the more metastatic prostate cancer cell lines PC3 and DU145 as compared to LNCaP. Even the more metastatic sublines of LNCaP, LNCaP-LN3 and LNCaP-Pro5 expressed higher levels of VEGF-C compared to the parental line. Our focus in this study was to understand the mechanism of VEGF-C expression in prostate cancer, specifically in the context of androgen-deprivation conditions. We observed a timedependent increase in VEGF-C mRNA levels when LNCaP cells were cultured in media containing charcoal-dextran-treated serum (reduced androgen containing serum). This increase in VEGF-C mRNA levels was inhibited after supplementing the media with the synthetic androgen R1881. This result therefore confirms the previous findings (Ruohola et al., 1999 ) that androgens have a negative regulatory effect on VEGF-C expression and suggests a potential functional significance for higher VEGF-C levels during the initial stage of androgen withdrawal. Interestingly, we observed a decrease in VEGF-A mRNA levels in LNCaP cells upon androgen depletion, confirming previous findings that androgen positively regulates VEGF-A mRNA transcription. These observations describe a potentially unique role for VEGF-C in androgen regulation.
Insight into a possible cellular mechanism for the elevation of VEGF-C levels under androgen-depleted conditions came with the observation that inhibition of the IGF-IR signaling pathway in LNCaP cells lead to the upregulation of VEGF-C mRNA. A recent report suggested that androgen stimulation of LNCaP cells cultured in media containing charcoal-dextran-treated serum leads to an increase in IGF-IR protein expression (Arnold et al., 2005) . The activation of PI3K pathway by androgen was also reported previously (Baron et al., 2004; Castoria et al., 2004; Kang et al., 2004) . These reports, together with our observation of higher VEGF-C mRNA levels after inhibiting IGF-IR signaling supports the conclusion that androgen deprivation leads to a decrease in IGF-IR expression that in turn increases the transcription of VEGF-C. This negative regulation of VEGF-C transcription by IGF-IR might be specific for prostate cancer. Recently, Tang et al. (2003) demonstrated a positive regulation of VEGF-C transcription by IGF-IR in Lewis lung carcinoma subline, M27. These differences in IGF-IR signaling for VEGF-C transcription therefore pointed out the heterogeneity of cellular signaling in different cancers and also in the different stages of a particular cancer. FOXO-1 is a member of the forkhead transcription factor family whose transcriptional activity is negatively regulated by IGF-IR (Morris et al., 1996; Borkhardt et al., 1997; Lin et al., 1997; Ogg et al., 1997; Kops and Burgering, 1999) and is therefore a potential downstream target of IGF-IR in VEGF-C transcription. Interestingly, we have found several potential binding sites for FOXO-1 in the VEGF-C promoter region using Genomatix software. To show that FOXO-1 is the probable transcription factor for VEGF-C, we have overexpressed FOXO-1 in LNCaP cells. A significant increase in VEGF-C mRNA was observed in LNCaP cells overexpressing FOXO-1. The target genes for FOXO-1 include both the proapoptotic genes as well as the genes involved in stress resistance. Recently, a protein called SIRT1 has been shown to regulate FOXO-1 activity by enhancing the transcription of stress resistance genes but diminished the expression of proapoptotic genes such as Fas ligand and BIM. SIRT1 specifically deacetylates FOXO-1 in order to regulate its activity (Araki et al., 2004; Brunet et al., 2004; Cohen et al., 2004; Daitoku et al., 2004) . The finding that VEGF-C transcription driven by FOXO-1 requires SIRT1 suggests that VEGF-C is another survival related target gene of FOXO-1. In this study, we have therefore suggested a possible mechanism of VEGF-C transcription resulting from androgen ablation in the prostate cancer cell line, LNCaP. Androgen ablation decreases IGF-IR expression and therefore disrupts its function. The resulting effect is activation of FOXO-1, which with SIRT1, increases the transcriptional activity of VEGF-C. VEGF-C can potentiate different functions in prostate cancer, many of which may be responsible for its growth and survival in the androgen-withdrawal stage. Particularly, increased synthesis of VEGF-C may be linked to its early and mid-phase transition to the highly metastatic, and androgen-refractory stage. The main function of VEGF-C is its involvement in lymphangiogenesis where the growth and sprouting of lymphatic endothelium occurs from a pre-existing lymphatic vessel (Skobe et al., 2001) . Increased lymphatic vessel formation surrounding a tumor may provide potential routes for tumor cells to metastasize to distant organs. As androgen withdrawal triggers tumor growth arrest and tumor apoptosis in the primary site, an increase in the metastatic potential therefore helps the tumor cells to migrate to a different location and survive. Interestingly, there are reports that suggest a significant correlation between the expression of VEGF-C and lymph node dissemination in human prostate carcinoma (Tsurusaki et al., 1999) . Moreover, the number of vessels positive for VEGFR-3, the receptor of VEGF-C, was increased in the surrounding stromal tissue of VEGF-C-positive prostatic carcinoma cells (Tsurusaki et al., 1999) . Therefore, it will be interesting to study the involvement of lymphangiogenesis in prostate cancer metastasis during its transition to the androgen-refractory stage.
As VEGF family members are usually multifunctional in nature, we were also interested in identifying VEGF-C functions distinct from lymphangiogenesis that may be responsible for prostate cancer progression. We tested for the presence of VEGFR2 and VEGFR3, two receptors for VEGF-C in LNCaP cell lines with real-time PCR. We detected a very low level of VEGFR-3 in LNCaP cells, but VEGFR-2 was in the detectable level and B10-fold higher than VEGFR-3 under our experimental conditions (Figure 5a ). This result suggests a possible VEGF-C autocrine loop in prostate cancer cells and possibly some VEGFR-2 specific functions in LNCaP. The concept of autocrine loop for VEGF family members in prostate cancer cells were further supported by the recent report of Steiner et al. (2004) . The authors reported VEGF-A-VEGFR2-mediated autocrine loop in LNCaP cells after prolonged IL6 treatment. Along these lines, LNCaP cells also provide a unique opportunity to study the specific functions of VEGF-C and VEGFR-2 that are currently unclear.
The finding that BAG-IL (long isoform of Bag-1) was increased in serum-starved LNCaP after VEGF-C treatment is also significant. Bag-IL is a member of the Bcl-2 family and plays a role in cell survival during stress conditions. Bag-l(Bcl-2-associated athanogene 1) is a family of proteins that associates with the molecular chaperone Hsp70 and serves as a nucleotide exchange factor for this protein. There are four mammalian isoforms of Bag-1; Bag-lL, Bag-IM, Bag-lS, and p29, generated by alternative translation initiation sites on the same mRNA. The human Bag-IL protein migrates as a 57-58 kDa protein in SDS-PAGE experiments. The Bag-1 proteins have multiple biological functions ranging from inhibition of apoptosis to modulation of the action of steroid receptors. Bag-IL has been reported to enhance the transactivation function of the androgen receptor with the help of Hsp70. Furthermore, Bag-IL is expressed in prostate cancer specimens (Froesch et al., 1998; Sadar et al., 1999; Shatkina et al., 2003) . Therefore, a VEGF-C-induced increase in Bag-IL may enhance transactivation of androgen receptor even in low concentrations of androgen.
In conclusion, we have observed an increase in the VEGF-C level in prostate cancer cells due to the withdrawal of androgens. We have delineated a possible mechanism for VEGF-C synthesis in LNCaP cells involving the androgen-IGF-IR-FOXO-1 pathway. Finally, we also determined a potential function mediated by VEGF-C that may be important for the growth and survival of prostate cancer from the early phase of its transition to the androgen-refractory stage.
Materials and methods
Cell culture and reagents
Human prostate cancer cell line, LNCaP (ATCC # CRL-1740), DU-145 (ATCC # HTB-81), and PC-3 (ATCC #CRL-1435), were maintained in RPMI medium and Ham's F-12 medium separately with 10% fetal bovine serum (HyClone Laboratories, Logan, UT, USA). LNCap-LN3 and LNCappro5 were kind gifts from Dr Curtis A Pettaway of MD Anderson. FOXO-1 expression vector was obtained from Dr Haoji Huang of Mayo Clinic. Human SIRT1 dominantnegative (DN) plasmid (pECE-SIRTlDN) was also a kind gift from Dr Michael E Greenberg, Children's Hospital and Harvard Medical School, Boston. NLP-005 Methyltrienolone (R1881) were purchased from Sigma-Aldrich (St. Louis, MO, USA). BML-210 was purchased from BIOMOL International L.P. (Plymouth Meeting, PA, USA).
Transfection and whole cell extract preparation
LNCaP cells (5 Â 10 5 cells) were seeded in 60 mm dish 1 day before transfection. Transfection was carried out with Effectene Transfection Kit (Qiagen, Valencia, CA, USA). Briefly, 0.5 mg of the FOXO-1 expression plasmid was resuspended in EC buffer (75 ml) and 4 ml of Enhancer was added and incubated at room temperature for 5 min. Effectene (10 ml) was then added and the whole mixture was incubated for another 10 min. RPMI with 10% FBS (350 ml) was added to the DNA mixtures. At 48 h after transfection, cells were washed three times with PBS, whole cell extracts was prepared in accordance to the following protocol.
Preparation of whole cell extracts
LNCaP, DU145, PC-3, LNCap-LN3 and LNCap-Pro5 cells were washed twice with 10 ml of cold PBS, lysed with ice-cold RIPA lysis buffer (50 mM Tris (pH 7.5), 1% Nonidet p-40 (NP-40), 150 mM NaCl, 1 mM Na 3 VO 4 , 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, leupeptin (10 mg/ml), 0.5% aprotinin, 2 mM pepstatin A), incubated on ice for 30 min, and centrifuged at 14 000 r.p.m. at 41C for 10 min.
Western blot analysis
The whole cell extracts were separated by SDS-PAGE; immunodetection antibodies against VEGF-C (R&D System, Inc., Minneapolis, MN, USA), Flag (Sigma), IGF-IRa (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), Bag-1 (Zymed Laboratories Inc., South San Francisco, CA, USA) were used, followed by the secondary antibody incubation, and detected by ESL enhancer reagent from Amersham Biosciences Corp (Piscataway, NJ, USA).
ELISA
Cell culture supernatant was collected after growing the prostate cancer cells at serum-starved media for 24 h. VEGF-C was measured in the cell culture supernatant using a commercial ELISA kit (Zymed laboratories Inc.) according to the manufacturer's protocol. Briefly, after incubation 100 ml of sample media or different dilutions of standard in the plate at 371C for 1 h, the wells were washed three times with washing buffer, 100 ml of labeled antibody solution was added to each well for a 30 min incubation at 41C. For color development, TMB buffer (100 ml) was added into the wells and was incubated for 30 min at room temperature in dark, the reaction was stopped by adding 100 ml of Stop solution. Color intensity was measured by a plate reader at 450 nm. Data represent the average of three different assays.
Treatment of cells with antibody, androgen and specific SIRT inhibitor 2000), R1881, BML-210 (specific SIRT inhibitor) and recombinant VEGF-C protein at 371C for different time points. Cells were serum starved before IGF-IRa antibody, BML-210 and recombinant VEGF-C protein treatment. For R1881, cells were cultured in charcoal-dextran-treated serum for 48 h. After washing twice with ice-cold PBS, cells were lysed using lysis buffer from the RNeasy Mini kit (Qiagen). Total RNA was extracted according to the RNeasy mini kit protocol.
RNA preparation and real-time PCR
After washing twice with ice-cold PBS, different cell lines LNCaP and other cells were lysed using lysis buffer from the RNeasy Mini kit (Qiagen). Total RNA was extracted according to the RNeasy mini kit protocol. We used the Taqman real-time PCR method. The sequence for forward, reverse and Taqman middle primers for human VEGF-C, VEGF-A, VEGFR2, VEGFR3 and for human 36B4 (housekeeping gene) were taken from the PubMed gene bank and synthesized (Integrated DNA Technology). 36B4 is a ribosomal RNA and ubiquitously expressed in all the cells. Owing to its housekeeping function, it is used as a control experiment for CCC GCG AA-3 0 . Each real-time PCR reaction was conducted using 0.5 mg total RNA, 25 ml RT-PCR Master Mix (Applied Biosystems), 1.25 ml RNase inhibitor (Applied Biosystems), 50 nM forward primer, 50 nM reverse primer, and 100 nM middle primer. For reverse transcription, a 30-min period at 481C was run before inactivating the reverse transcriptase at 951C for 10 min. A total of 40 cycles at 951C for 15 s and 601C for 1 min was performed with an ABI Prism 7700 Sequence Detector (Applied Biosystems). All experiments were carried out three times and from each of the three, triplicate readings were taken and the average was calculated.
Relative RNA amount was calculated as follows: The cycle number (CT) at which PCR amplification took place in a particular threshold value in the exponential phase for each reaction was determined by the sequence detector. Real-time PCR for the housekeeping gene, 36B4 was performed for each test sample along with VEGF-C or VEGF-A. To normalize the value of VEGF-C or VEGF-A for each reaction condition, the value of 36B4 at that condition was deducted and the resulting value was designated as D. Therefore, D ¼ CT (VEGF-C or A sample)ÀCT(36B4 sample). To calculate the relative expression of the treated sample compare to the control sample, first DD was determined by deducting the D value of the control sample from the treated sample. Therefore, DD ¼ D (transfected or treated sample)ÀD(empty vector or untreated sample). Finally, relative RNA amount in comparison to the control was calculated by using the formula, 2 ÀDD . Average and standard deviations from three experiments were calculated.
